

Video Article

# Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Zhifeng Huang<sup>\*1</sup>, Wenting Luo<sup>\*1</sup>, Xiangwei Zou<sup>1</sup>, Xiaqing Liu<sup>1</sup>, Chuanxu Cai<sup>1</sup>, Zehong Wu<sup>1</sup>, Haisheng Hu<sup>1</sup>, Baoqing Sun<sup>1</sup>

<sup>1</sup>State Key Laboratory Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University

\* These authors contributed equally

Correspondence to: Baoqing Sun at [sunbaoqing@vip.163.com](mailto:sunbaoqing@vip.163.com)

URL: <https://www.jove.com/video/59100>

DOI: [doi:10.3791/59100](https://doi.org/10.3791/59100)

Keywords: biochip, microfluidics, BioC, specific IgE, allergy, diagnosis

Date Published: 3/27/2019

Citation: Huang, Z., Luo, W., Zou, X., Liu, X., Cai, C., Wu, Z., Hu, H., Sun, B. Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE). *J. Vis. Exp.* (), e59100, doi:10.3791/59100 (2019).

## Abstract

Allergic disease is common in both adults and children. Identification of the causative allergens is significant in disease management and prevention. However, a specific immunoglobulin E (IgE) measurement system with a high price-performance ratio is lacking in mainland China, especially in the primary care hospitals. This paper describes the principle and operation procedures of using a microfluidic cartridge-based chemiluminescence system to detect allergen-specific IgE in serum. The results were compared with those from ImmunoCAP (System 1), the industrial standard, and the reproducibility of the system to detect patients sensitized to common allergens is evaluated. The results showed that in comparison with ImmunoCAP (System 1), the BioC System (System 2) has good precision and sensitivity in detecting serum-specific IgE against various inhalant and food allergens but with a significantly lower cost. It can serve as a good alternative to System 1 in primary care hospitals in mainland China who have lower financial affordability.

## Video Link

The video component of this article can be found at <https://www.jove.com/video/59100/>

## Introduction



The prevalence of allergies has increased steadily in the past decades and is affecting 20%-30% of the global population<sup>1</sup>. Identification of the causative allergens has important significance in managing the diseases. In China, since registered in vivo skin prick tests are not available in the country, in vitro determination of serum-specific IgE is the most important and commonly used tool for type I allergy diagnoses<sup>2</sup>. This is similar to practices in the Western world, but although **System 1**, a fluorescence enzyme-linked immunosorbent base system, is perceived as the gold standard for in vitro allergy diagnosis<sup>3</sup>, its usage in China is very limited due to its high equipment and reagent price. Hence a new alternative allergy diagnosis system with a high price-performance ratio is badly needed.

The BioC System (System 2) is a microfluidic cartridge-based system based on the chemiluminescence principle for multiplexed assays of serum-specific IgE. With a size of 7 cm x 4 cm, the microfluidic cartridge is composed of three layers of injection-molded plastic. The upper part is 3 mm-thick transparent polycarbonate which carries good stability during thermal assembly processes. Together with the 3 mm-thick bottom layer constructed from a copolymer of acrylonitrile, butadiene, and styrene (ABS), it sandwiches the 0.5 mm-thick middle layer made of silicone rubber. Being black in color, the middle layer offers lower background during chemiluminescence detection. On top of the silica gel, a thin layer of nitrocellulose membrane (NC membrane) is sprayed at the position corresponding to the reaction zone, which allows the spotting of different allergenic proteins. The purpose of this study is to evaluate the clinical performance of the microfluidic system for the multiplexed determination of allergen-specific IgE in serum.

## Protocol

This study and the use of human serum samples were approved by the Ethics Committee of The First Affiliated Hospital of Guangzhou Medical University (GYYY-2016-73). All participants have given their written consent independently or through their parents (in the case of children).

## 1. Basic information of the study group

NOTE: The Allergy Information Repository of the State Key Laboratory of Respiratory Disease (AIR-SKLRD) is a large serum bank established inside the Guangzhou Institute of Respiratory Hospital (GIRH). Initiated in the last decade, the AIR-SKLRD has already started to collect and

store serum samples from patients with allergic diseases, together with their clinical information (**Table 1**)<sup>4,5</sup>. The current study was performed with sera from the AIR-SKLRD.

1. Search the AIR-SKLRD's database for sera collected from January 2015 to June 2018 and select the patients with allergic disease, who were found to be sensitive to the common allergens in the region.
2. Ensure that all selected patients have allergic-related diseases, such as allergic rhinitis and or asthma, allergic dermatitis, and/or urticaria, and that the serum of these patients contains multiple serum allergen-specific immunoglobulin E (sIgE) sensitizations of common allergens in this region, detected by the System 1.
3. Exclude patients with incomplete medical records, those lost to follow-up, those who refuse to give informed consent regarding the use of their serum samples for scientific purposes, those with an identified immunodeficiency, those currently on immunotherapy or immunomodulatory agents, or those found to have parasitic infections.
4. Ensure no treatment or drug prescription was given prior to the serum collection so as to minimize interference to the laboratory findings. All serum samples that do not fulfill the criteria were rejected.

## 2. Study flow and measurements of interest

NOTE: The microfluidic system needs 100  $\mu$ L of serum for determining 19 allergens. Venous blood (5 mL) was collected from each patient using a vacuum blood vessel containing separating gel. After centrifuging for 10 min at 1,000  $\times$  g, the upper layer was collected for testing. Unused serum was stored at -80 °C. Prior to testing, the serum was kept at room temperature for 30 min and was shaken with a vortex mixer. Repeated freeze-and-thaw cycles were avoided.

1. Primarily test the serum samples for sIgEs to whole allergens of *Dermatophagoides pteronyssinus* (d1), *Dermatophagoides farinae* (d2), *Blomia tropicalis* (d201), cat dander (e1), dog dander (e5), Bermuda grass (g2), timothy grass (g6), cockroaches (i6), *Aspergillus fumigatus* (m3), *Candida albicans* (m5), ragweed (w1), egg white (f1), milk (f2), wheat (f4), peanut (f13), soybean (f14), almond (f20), crab (f23), and shrimp (f24). Follow the instructions given in section 3.  
NOTE: sIgE determination was done with the allergen-specific IgE assay kit (see the **Table of Materials**) and measured by a chemiluminescence analyzer.
2. Randomly select three samples from among the samples with enough serum (at least 900  $\mu$ L) for a reproducibility study. Keeping all the conditions unchanged, measure the three sera for allergen sIgEs daily for 9 consecutive days (i.e., a total of 100  $\times$  9 = 900  $\mu$ L of serum).

## 3. Semi-automation test procedure of the microfluidic system

NOTE: The System 2 is the integration of automatic microfluidic technology, protein microarray, cold light analysis, parallel IgE analysis, and image processing technology. The testing protocol is divided into four parts: preparation of the equipment, sample loading, incubation, and measurement.

1. **Preparation of the equipment**
  1. Turn on the PC and the analyzer power.  
NOTE: The power switch is on the left of the base.
  2. Start the LabIT program on the PC. If the **Dark Frame** warning window pops up, click **OK** to run **LEAK Test**. Afterward, click the center logo to enter the operation interface.  
NOTE: The system will remind the user to run **LEAK Test** if it is idle for more than 24 h.
  3. Check the Reaction Temp and CCD (charge-coupled device) Temp at the lower right corner of the screen. The Reaction Temp should rise to 37 °C  $\pm$  1 °C in about 10 min, and the CCD Temp should drop to -15 °C  $\pm$  1 °C.
  4. Run the **LEAK Test** after the CCD Temp has dropped to -15 °C  $\pm$  1 °C. Before running the LEAK test, make sure there are no other items left inside the instrument and close the door. Click **Tools** | **System Test** | **LEAK Test**. Do not open the door during testing. When the test is finished, the report window will pop up.
2. **Sample loading**
  1. Add 620  $\mu$ L of wash buffer, 120  $\mu$ L of blocking buffer, 60  $\mu$ L of conjugates A and B, 60  $\mu$ L of substrate A and B, and 100  $\mu$ L of serum samples to the corresponding reagent tank on the microfluidic cartridge.
3. **Incubation**
  1. Click on **Cartridge ID**, use the barcode scanner to scan the serial number of the cartridge, enter the sample ID, put the cartridge into the analyzer and close the door, and click **Analyzer** and **Run** to start the analysis.
4. **Measurement**
  1. Export the results to statistical software (e.g., Excel) after the measurement.  
NOTE: After 30 min of incubation, the analyzer automatically performs the measurement and reports the result.
5. **Switching off of the analyzer**
  1. For routine maintenance, after finishing the test, remove the cartridge and wipe the analyzer's internal heating iron and electromagnet lightly with 75% alcohol.  
NOTE: Do not press hard or shake the electromagnet.
  2. Close the LabIT window. The temperature monitoring window will pop up. It will automatically close when the CCD warms up to the 5 °C protection mode. By then, it will be safe to turn off the power of the analyzer and PC.  
NOTE: Do not manually close the temperature monitoring window before the CCD Temp has risen to 5 °C, and do not turn off the power of the analyzer nor the PC during the CCD warm-up.

## 4. Definition of sIgE reactivity

NOTE: For an undiluted serum specimen, the detection range of the System 2 is 0.21–100 IU/mL.

- Based on the threshold value of 0.35 IU/mL, consider an sIgE level exceeding 0.35 IU/mL to be positive<sup>6,7</sup>. Rate the reactivity of the sIgE tests as<sup>8</sup>: class 1 ( $\geq 0.35$  and  $< 0.70$  IU/mL), class 2 ( $\geq 0.70$  and  $< 3.50$  IU/mL), class 3 ( $\geq 3.50$  and  $< 17.50$  IU/mL), class 4 ( $\geq 17.50$  and  $< 50.00$  IU/mL), class 5 ( $\geq 50.00$  and  $< 100.00$  IU/mL), and class 6 ( $\geq 100.00$  IU/mL).

## 5. Statistical analysis

- Use a histogram to show the positive rate of the 19 allergens (**Figure 1**) and use the Levey-Jennings curve to demonstrate the repeatability of the detection system (**Figure 2**)<sup>9</sup>.
- Select the three most common inhalant allergens and food allergens (in total, six allergens) and compare the results to the System 1 to evaluate its clinical diagnostic performance<sup>10,11</sup>. Include the concordance rate, sensitivity, specificity, positive and negative predictive values, and the area under the receiver operating characteristic (ROC) curve (AUC) as the evaluation criteria.
- Apply Spearman's correlation analysis<sup>12</sup> to describe correlations between the two systems and use kappa value for consistency. Categorize the kappa value as almost perfect (0.8–1.0), substantial (0.6–0.8), moderate (0.4–0.6), fair (0.2–0.4), or poor ( $< 0.2$ )<sup>13</sup>. Use SPSS 23.0 and MedCalc 11.0 statistical analysis and define  $P < 0.05$  as statistical significance.

## Representative Results

### Positive rates for 19 common allergens

The results on 293 sera are shown in **Figure 3**. Among all the inhalant allergens, *D. farinae* had the highest positive rate (80.89%, 273/293), followed by *D. pteronyssinus* (78.84%, 231/293). Among the food allergens, crab has the highest positive rate (20.48%, 60/293), followed by 13.65% (40/293) for shrimp. The total positive rate for inhalant allergens was higher than that for food allergens.

### Repeatability of the microfluidic system


Repeatability results for cat dander, dog dander, and cockroach, based on nine rounds of testing, were  $32.98 \pm 8.94$ ,  $1.61 \pm 0.48$ , and  $0.76 \pm 0.18$ , respectively, and the consistency levels were 100% (9/9), 100% (9/9), and 67% (6/9). Distribution of the results is shown with the Levey-Jennings curve in **Figure 2**. All data are within the range of  $\bar{X} \pm 2 \times \text{SD}$ , which is consistent with the maximum allowable clinical error<sup>14</sup>.

### Comparison of two systems


Qualitative results showed that cat dander had the highest concordance to System 1 (95.33%, 243/150). The lowest concordance was seen in shrimp (40.75%, 88/216). The total concordance among inhalant allergens ranged from 92.00% to 95.33%. For food allergens, the concordance range was 40.74%–72.39%. The highest sensitivity for inhalants was seen in *Dermatophagoides farinae* (93.94%), with a 100% specificity. Among food allergens, the highest sensitivity was seen in peanut (54.55%), with a specificity of 80.65%. **Table 2** also shows that all the evaluation results for inhalant allergens were superior to food allergens. Since the AUC values showed a range from 0.613 to 0.984 and the AUC for the three inhalant allergens was greater than 0.950, it can be concluded that the System 2 has a high accuracy with reference to System 1.

Consistency analysis for the two systems showed that the kappa values for the three inhalants were between 0.727–0.876, with the highest value seen in cat dander as 0.876 (95% CI, 0.0786–0.965). They were all better than the kappa values for food allergens which, in general, fell  $< 0.400$ . The lowest kappa value was 0.112 in shrimp (95% CI, 0.062–0.162) (**Table 3**). Spearman's correlation analysis showed that the best correlation was seen in peanut and cat dander, with correlation coefficients as  $r = 0.942$  (95% CI, 0.907–0.965;  $p < 0.0001$ ) and  $r = 0.927$  (95% CI, 0.900–0.947;  $p < 0.0001$ ), respectively.


In **Figure 3**, a scatter plot is constructed with System 2's results along the x-axis and System 1's along the y-axis to show the distribution of the sIgE concentration results from the two systems for *D. pteronyssinus*, *D. farinae*, cat dander, milk, shrimp, and peanut. For a concordance and discordance analysis, the allergens that showed  $\pm 1$  class difference were *D. pteronyssinus* (91.60%, 229 vs. 250), *D. farinae* (81.25%, 91 vs. 112), cat dander (98.00%, 147 vs. 150), milk (83.58%, 112 vs. 134), shrimp (59.72%, 129 vs. 216), and peanut (76.56%, 49 vs. 64). The combined total concordance rate was 81.75% (757 vs. 926).



**Figure 1: The positivity rates of the detection of 19 common allergens by the microfluidic assay.** d1 = *Dermatophagoides pteronyssinus*, d2 = *Dermatophagoides farinae*, d201 = *Blomia tropicalis*, e1 = cat dander, e5 = dog dander, g2 = Bermuda grass, g6 = timothy grass, i6 = cockroaches, m3 = *Aspergillus fumigatus*, m5 = *Candida albicans*, w1 = ragweed, f1 = egg white, f2 = milk, f4 = wheat, f13 = peanut, f14 = soybean, f20 = almond, f23 = crab, and f24 = shrimp. [Please click here to view a larger version of this figure.](#)



**Figure 2: Levey-Jennings graphs of the three allergens repeatedly detected by the microfluidic system.** (A) Cat hair, (B) dog hair, and (C) cockroach were selected for repeatability evaluation. The black, green, yellow, and red lines represent the mean ( $\bar{X}$ ), the mean  $\pm$  the standard deviation ( $\bar{X} \pm SD$ ), the mean  $\pm$  the standard deviation times two ( $\bar{X} \pm 2SD$ ), and the mean  $\pm$  the standard deviation times three ( $\bar{X} \pm 3SD$ ) of multiple measurements, respectively. [Please click here to view a larger version of this figure.](#)



**Figure 3: Scatter plots of six allergen sIgE concentrations measured by System 1.** System 1 (Y-axis) and the System 2 **System** (X-axis). Each line in the plot represents class cutoffs (class 0: 0.35, class 1: 0.35–0.7, class 2: 0.7–3.5, class 3: 3.5–17.5, class 4: 17.5–50, class 5: 50–100, and class 6: >100 **kU/L**). Shaded boxes are concordant areas in the concentration class. [Please click here to view a larger version of this figure.](#)

Characteristic	No.(%)
<b>Gender, n(%)</b>	
Female	123(41.98%)
male	170(58.02%)
<b>Age, year, n(%)</b>	
Median (25%,75%)	23(8,36)
≤10	97(33.11%)
11-20	37(12.63%)
21-40	101(34.47%)
>41	58(19.80%)
<b>Diagnosis, n(%)</b>	
Allergic rhinitis	92(31.40%)
Allergic asthma	117(39.93%)
Allergic rhinitis with asthma	36(12.29%)
Others	48(16.38%)

Totally 293 subjects were found to fulfill the inclusion criteria, with an average age of 23 (range from 8 to 36 years old). Among them, 170(58.02%) were male and 123(41.98%) were female. 92(31.40%) of them had allergic rhinitis, 117(39.93%) had allergic asthma, 36(12.29%) with comorbidity of rhinitis and asthma, and 48(16.38%) had other allergic diseases such as food allergy, skin allergies, etc.

**Table 1: Patient demographic characteristics.** In total, 293 subjects were found who fulfilled the inclusion criteria, with an average age of 23 (with a range from 8 to 36 years old). Among them, 170 (58.02%) were male and 123 (41.98%) were female. Also, 92 (31.40%) of them had allergic rhinitis, 117 (39.93%) had allergic asthma, 36 (12.29%) had comorbidity of rhinitis and asthma, and 48 (16.38%) had other allergic diseases, such as a food allergy or skin allergies.

	Sample size	CAP +		CAP -		Total agreement	SE	SP	PPV	NPV	AUC(95%, CI)
		BiolC +	BiolC -	BiolC +	BiolC -						
<b>d1</b>	250	196	20	0	34	92.00%	#####	#####	#####	#####	0.975(0.947 to 0.991)
<b>d2</b>	112	93	6	0	13	94.64%	#####	#####	#####	#####	0.984(0.947 to 0.999)
<b>e1</b>	150	34	5	2	109	95.33%	#####	98.20%	94.44%	#####	0.968(0.925 to 0.990)
<b>f2</b>	134	16	27	10	81	72.39%	#####	89.01%	61.54%	#####	0.744(0.667 to 0.815)
<b>f13</b>	64	18	15	6	25	67.19%	#####	80.65%	75.00%	#####	0.731(0.606 to 0.834)
<b>f24</b>	216	36	127	1	52	40.74%	#####	98.11%	97.30%	#####	0.613(0.545 to 0.678)

d1-Der. p1, d2- Der. f1, e1-Cat dander, f2-Milk, f13-Peanut, f24-Shrimp. CAP-ImmunoCAP, +-positive, --negative, SE-sensitivity, SP-specificity, PPV-positive predictive value, NPV-negative predictive value, AUC-area under the ROC curve. For AUC values, the 95% interval value (95%, CI) is also shown in the table.

**Table 2: Clinical performance between the two systems.** d1 = *D. pteronyssinus*, d2 = *D. farina*, e1 = cat dander, f2 = milk, f13 = peanut, and f24 = shrimp. CAP = ImmunoCAP, + = positive, - = negative, SE = sensitivity, SP = specificity, PPV = positive predictive value, NPV = negative predictive value, AUC = area under the ROC curve. For the AUC values, the 95% interval value (95%, CI) is also shown in the table.



	Kappa(95%,CI)	Spearman's rho(95%,CI)
d1	0.727(0.617 to 0.838)	0.896(0.869 to 0.918)
d2	0.783(0.617 to 0.948)	0.731(0.631 to 0.807)
e1	0.876(0.786 to 0.965)	0.927(0.900 to 0.947)
f2	0.293(0.122 to 0.463)	0.681(0.579 to 0.763)
f13	0.349(0.129 to 0.569)	0.969(0.949 to 0.981)
f24	0.112(0.062 to 0.162)	0.833(0.788 to 0.870)

d1-Der. p1, d2- Der. f1, e1-Cat dander, f2-Milk, f13-Peanut, f24-Shrimp. For kappa and Spearman's rho values, the 95% interval value (95%, CI) is also shown in the table.

**Table 3: Correlation and agreement between the two systems.** d1 = *D. pteronyssinus*, d2 = *D. farinae*, e1 = cat dander, f2 = milk, f13 = peanut, and f24 = shrimp. For kappa and Spearman's Rho values, the 95% interval value (95%, CI) is also shown in the table.

## Discussion

Similar to the results from many other studies<sup>15,16,17</sup>, the results from the microfluidic system based on sera from 293 allergic patients showed that house dust mites (including *D. pteronyssinus*, *D. farinae*, and *B. tropicalis*) are the main inhalant allergens leading to allergic diseases in southern China, whereas for food, milk, peanut, shrimp, and crab are the commonest allergens that cause allergic symptoms. With regard to the reproducibility study done on three allergens, all of them showed good results, with an overall repetition rate of 88.89%, which means it met the maximum allowable error.

Using System 1 as reference, the current study evaluated the clinical diagnosis efficacy of the System 2. With a serum sIgE level of 0.35 IU/mL as cutoff<sup>2</sup>, a sample with sIgE > 0.35 IU/mL implies that the patient is sensitive to the allergen, and the higher the titer, the better correlation to the patient's symptoms<sup>18</sup>. The results show that the concordance rate of the three inhalant allergens were all more than 90%. In addition to the results for food allergens, which had a concordance of ~40.74%-72.39%, the total concordance was 81.75% (757/926). The kappa value of *D. pteronyssinus*, *D. farinae*, and cat dander were 0.778, 0.663, and 0.860 ( $p < 0.001$ ), respectively. The kappa values for food allergens were all below 0.4. For the three major inhalant and food allergens, a significant correlation of quantitative results was seen between the two systems ( $r_{\text{Spearman}} \approx 0.681-0.969$ ,  $p < 0.01$ ).

It was noticed that while the  $r_s$  coefficient for peanut was 0.969, the kappa value of the consistency evaluation index was only 0.349 (95% CI, 0.129-0.569). Such discrepancy might be due to the low prevalence of peanut sensitivity in the region and, hence, most of the recruited sera were negative for that specific IgE. Many studies have indicated that a significant discrepancy could be seen between sIgE titer and clinical symptoms of food allergens. The use of different assay systems for food-specific IgE determination could also create big variations<sup>19</sup>. This might be due to the fact it is not the raw ingested food which triggers the allergic symptoms, but the modified components generated during cooking or digestion. The use of different raw materials by different manufacturers to make the allergens can also contribute to the result discrepancy<sup>20</sup>.

The microfluidic cartridge is composed of five major parts: five storage tanks, five reagent delivery channels, five unidirectional pumps, a single reaction zone in which allergen extracts can be immobilized, and a waste tank to collect all reaction by-products. Based on the assay need, up to 40 allergen extracts can be dotted on the reaction zone. Controlled by the PC, the five unidirectional pumps guide and coordinate the flow of serum sample, washing buffer, blocking reagent, conjugates, and substrates, to finish a two-step enzyme-linked immunosorbent assay. After the reaction is completed, the chemiluminescence reaction images are captured by a low-resolution cooled CCD camera and the signals are processed by the PC to establish the calibration curve and to calculate quantitative and semiquantitative sIgE results.

The current study shows that the two systems demonstrate good consistency. However, compared with the System 1, the System 2 is easier to use and has a lower demand for operator training. Since each microfluidic cartridge has its own quality control curve, the reliability of the system is greatly enhanced. Other advantages of the system include a light and small footprint, an expandable modular setup, and the ease with which it is connected to a PC for operation control. All these advantages greatly reduce the setup and running cost, and at the same time, they do not jeopardize the accuracy and speed requirements in daily clinical practice, which makes the system particularly suitable for allergy screening in primary care hospitals in China. Nevertheless, one major drawback of the microfluidic system is that it is not a fully automatic system, and frequent intervention is needed during the operation. It still cannot replace the systems that need to process a big number of samples daily.

Due to the lack of enough positive sera for certain allergens, this study did not cover all the 19 allergens available in the microfluidic cartridge, but just six common ones available in southern China. More study is needed to elaborate on whether the evaluation is also applicable to other allergens.

## Disclosures

The authors have nothing to disclose.

## Acknowledgments

The authors thank Professor Mei Jiang for her help in the statistical analysis and Mr. Hammer Tsui in the preparation of the manuscript. This study was supported by the Guangzhou Science and Technology Foundation (201804020043) and the National Natural Science Foundation of



China (NSFC 81572063 and NSFC 81802076). The funding groups agreed with the study design, data analysis, manuscript preparation, and decision to publish. No other funding was received for this study.

## References

1. Kamble, S., Bharmal, M. Incremental Direct Expenditure of Treating Asthma in the United States. *Journal of Asthma Research*. **46** (1), 73-80 (2009).
2. Paganelli, R. et al. Specific IgE antibodies in the diagnosis of atopic disease. Clinical evaluation of a new in vitro test system, UniCAP, in six European allergy clinics. *Allergy*. **53** (8), 763-768 (1998).
3. Wang, J., Godbold, J. H., Sampson, H. A. Correlation of serum allergy (ige) tests performed by different assay systems. *Journal of Allergy and Clinical Immunology*. **121** (5), 1219-1224 (2008).
4. Sun, B., Zheng, P., Wei, N., Huang, H., Zeng, G. Co-sensitization to silkworm moth (*Bombyx mori*) and 9 inhalant allergens among allergic patients in Guangzhou, Southern China. *PLoS ONE*. **9** (5), e94776 (2014).
5. Zeng, G. et al. Component-Resolved Diagnostic Study of Dermatophagoides Pteronyssinus Major Allergen Molecules in a Southern Chinese Cohort. *Journal of Investigational Allergology & Clinical Immunology*. **25** (5), 343-351 (2015).
6. Luo, W. et al. Major grass pollen allergens and components detected in a southern Chinese cohort of patients with allergic rhinitis and/or asthma. *Molecular Immunology*. **78** (2016), 105-112 (2016).
7. Zeng, G. et al. Longitudinal profiles of serum specific IgE and IgG4 to Dermatophagoides pteronyssinus allergen and its major components during allergen immunotherapy in a cohort of southern Chinese children. *Molecular Immunology*. **74** (2016), 1-9 (2016).
8. Lee, J. H. et al. Specific IgE measurement using AdvanSure(R) system: comparison of detection performance with ImmunoCAP(R) system in Korean allergy patients. *Clinica Chimica Acta*. **413** (9-10), 914-919 (2012).
9. Eckels, J. et al. Quality control, analysis and secure sharing of Luminex(R) immunoassay data using the open source LabKey Server platform. *Bmc Bioinformatics*. **14** (1), 145 (2013).
10. Bland, J. M., Altman, D. G. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet*. **327** (8476), 307-310 (1986).
11. Carletta, J. Assessing Agreement on Classification Tasks: The Kappa Statistic. *Computational Linguistics*. **22** (2), 249-254 (1996).
12. Shyur, S. D. et al. Determination of multiple allergen-specific IgE by microfluidic immunoassay cartridge in clinical settings. *Pediatric Allergy and Immunology*. **21** (4 Pt 1), 623-633 (2010).
13. Cesana, B. M., Antonelli, P., Gallazzi, E., Marino, A. Comparison of measurement methods: an endless application of wrong statistical methods. *Intensive Care Medicine*. **37** (6), 1038-1040 (2011).
14. Park, K. H., Lee, J., Sim, D. W., Lee, S. C. Comparison of Singleplex Specific IgE Detection Immunoassays: ImmunoCAP Phadia 250 and Immulite 2000 3gAllergy. *Annals of Laboratory Medicine*. **38** (1), 23-31 (2018).
15. Teppo, H., Revonta, M., Haahtela, T. Allergic rhinitis and asthma have generally good outcome and little effect on quality of life - a 20-year follow-up. *Allergy*. **66** (8), 1123-1125 (2011).
16. Fischer, J. et al. Prevalence of type I sensitization to alpha-gal in forest service employees and hunters. *Allergy*. **72** (10), 1540-1547 (2017).
17. Li, J. et al. A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. *Allergy*. **64** (7), 1083-1092 (2009).
18. Ahlstedt, S. Understanding the usefulness of specific IgE blood tests in allergy. *Clinical & Experimental Allergy*. **32** (1), 11-16 (2002).
19. Wood, R. A., Segall, N., Ahlstedt, S., Williams, P. B. Accuracy of IgE antibody laboratory results. *Annals of Allergy Asthma & Immunology*. **100** (2), 288-289 (2008).
20. Aberer, W., Kränke, B., Hager, A., Wick, G. In vitro allergy testing needs better standardization--test results from different laboratories lack comparability mostly due to missing effective standards. *International Archives of Allergy & Immunology*. **108** (1), 82-88 (1995).